Introduction {#sec1}
============

Hepatocellular carcinoma (HCC) is the fourth-leading cause of cancer-related death worldwide.[@bib1] Despite significant progress, more than 70% of HCC patients cannot be diagnosed at an early stage, which is easier to treat via local ablation, hepatic resection, or liver transplantation.[@bib2]^,^[@bib3] Treatment is more difficult during later stages, and cancer recurrence and metastatic rates increase, leading to increased mortality.[@bib4], [@bib5], [@bib6] Therefore, the identification of novel molecular biomarkers of HCC and its prognosis and the elucidation of the detailed molecular mechanisms underlying HCC progression are of great importance.

G-protein-coupled receptors (GPCRs), or seven transmembrane (7TM)-spanning proteins, represent the largest class of cell surface receptor proteins, with approximately 800 members. GPCRs are important proteins in drug development and are reported to be key targets for more than 30% of drugs on the market.[@bib7] GPCRs were found to play dynamic roles in cancer development and progression, including survival and tumor growth.[@bib8]^,^[@bib9] Moreover, around 100 GPCRs have been classified as orphan GPCRs, because their endogenous ligands remain unidentified; however, several of them were reported to function in a ligand-independent manner.[@bib10]^,^[@bib11] They can facilitate signal transduction from the extracellular environment to intracellular effectors[@bib12] and mediate physiological and disease progression.[@bib13] A recent endeavor has strengthened the need to explore the vital role of GPCRs and their ligands, such as chemokines, lysophosphatidic acid (LPA), serine proteases (PAR1), and sphingosine 1-phosphate (S1P), in metastasis.[@bib14], [@bib15], [@bib16] Previously, pro-metastatic functions have been ascribed to numerous orphan GPCRs, such as GPR64, GPR116, and GPR161,[@bib10]^,^[@bib17]^,^[@bib18] highlighting the value of studying these receptors as novel therapeutic targets for preventing cancer metastasis.

GPR50, another member of orphan GPCRs, exhibits high sequence similarity with the melatonin receptors MT1 and MT2; however, melatonin is not a GPR50 ligand.[@bib19]^,^[@bib20] GPR50 was reported to be associated with bipolar-affective disorder, lipid metabolism, thermogenesis, adipogenesis, and neuronal development.[@bib21], [@bib22], [@bib23], [@bib24], [@bib25] In our previous study, several GPCRs, including GPR50, were claimed to be involved in the reprogramming of somatic cells to cancer stem cells and in the maintenance of stemness function.[@bib26] Recent studies also reported that *GPR50* can act as a tumor suppressor in breast cancer (BRC);[@bib27]^,^[@bib28] however, there is limited research on the role of *GPR50* in cancer progression.

In this study, we aimed to uncover the role of *GPR50* in HCC progression and prognosis. As *GPR50* was described as a tumor suppressor in breast cancer, we examined whether *GPR50* plays an oncogenic or a tumor-suppressor role in HCC. We found that *GPR50* is overexpressed in HCC and that *GPR50* knockdown can suppress HCC progression by downregulating the Notch signaling pathway. Our findings also indicate that GPR50 forms a novel molecular complex with a disintegrin and metalloproteinase (ADAM) metallopeptidase domain 17 (ADAM17) and regulates ADAM17 activity, activating the Notch signaling pathway in HCC in a ligand-independent manner. This pathway is also partially regulated by GPR50-mediated *ADAM17* transcription via the noncanonical AKT/specificity protein 1 (SP1) axis. Thus, our results support the potential of targeting HCC via the GPR50/ADAM17/Notch signaling pathway.

Results {#sec2}
=======

*GPR50* Is Differentially Expressed in Various Cancers and Associated with Liver Cancer Prognosis {#sec2.1}
-------------------------------------------------------------------------------------------------

Using the Oncomine database (<https://www.oncomine.org/resource/login.html>) to examine the expression status of *GPR50* in various cancers, we found dysregulated *GPR50* expression (Wooster cell line dataset) that was especially enhanced in BRC, cervical (CEC), esophagus (ESC), liver (HCC), and lung (LUC) cancers ([Figure 1](#fig1){ref-type="fig"}A). Subsequently, we analyzed *GPR50* mRNA expression in these cancers using several Gene Expression Omnibus (GEO) datasets. The GEO data showed that *GPR50* expression was significantly upregulated in liver cancers (i.e., HCC) and downregulated in breast, cervical, esophagus, and lung cancers ([Figure 1](#fig1){ref-type="fig"}B; [Table S1](#mmc1){ref-type="supplementary-material"}), which is in contrast with the expression patterns in the Oncomine database. Moreover, we analyzed the association between prognosis and *GPR50* expression in various cancer patients using The Cancer Genome Atlas (TCGA) database via the SurvExpress web. Among the indicated cancers, high *GPR50* expression exhibited a significant (p = 0.0118), poor prognostic role in HCC, whereas a nonsignificant prognostic role was found for other cancers, including breast, cervical, esophagus, and lung cancers ([Figure 1](#fig1){ref-type="fig"}C), suggesting a differential prognostic role of *GPR50* in various cancers. Thus, these results indicate that *GPR50* may have an oncogenic role in liver cancer.Figure 1*GPR50* Is Differentially Expressed in Various Cancer Types(A) Oncomine database Log2 median-centered expression intensities for *GPR50* genes in various cancers, such as bladder (BLC; n = 9), brain and CNS cancer (BCC; n = 16), breast (BRC; n = 19), cervical (CEC; n = 7), colorectal (COC; n = 23), esophageal (ESC; n = 4), gastric (GAC; n = 5), head and neck (HNC; n = 6), kidney (KIC; n = 8), leukemia (LEU; n = 30), liver (HCC; n = 9), lung (LUC; n = 73), lymphoma (LYM; n = 38), melanoma (MEL; n = 12), myeloma (MYE; n = 5), ovarian (OVC; n = 5), pancreatic (PAC; n = 9), prostate (PRC; n = 3), and sarcoma (SAR; n = 17) cancers. (B) Analysis of GEO: [GSE1477](ncbi-geo:GSE1477){#intref0040}, [GSE7803](ncbi-geo:GSE7803){#intref0045}, [GSE20347](ncbi-geo:GSE20347){#intref0050}, [GSE45436](ncbi-geo:GSE45436){#intref0055}, and [GSE2514](ncbi-geo:GSE2514){#intref0060} datasets for *GPR50* mRNA expression in BRC (n = 28), CEC (n = 31), ESC (n = 34), HCC (n = 134), and LUC (n = 39) compared with normal breast, cervical, esophageal, liver, and lung tissue. Other GEO datasets for BRC, CEC, ESC, HCC, and LUC cancers were incorporated into [Table S1](#mmc1){ref-type="supplementary-material"}. (C) Kaplan-Meier curves for clinical outcomes of patients with breast (n = 962), cervical (n = 191), esophageal (n = 184), liver (n = 361), and lung (n = 475) cancers, respectively, with high (red) and low (green) expression levels of *GPR50*. (D) *GPR50* mRNA expression in HCC. Boxplot generated by the SurvExpress web shows *GPR50* expression levels and the p value (t test of differences in TCGA RNA sequencing \[RNA-seq\] dataset). Low-risk (n = 191) and high-risk (n = 190) groups are shown in green and red, respectively. (E) *In silico* examination using cBioPortal reveals that 2.9% of samples had alterations in *GPR50* expression in HCC TCGA PanCan data (n = 348). (F) GPR50 expression was analyzed by RT-PCR and western blotting in the indicated normal hepatic cell line and different HCC cell lines. *GAPDH*/actin were used as a loading control.

We further examined *GPR50* expression in liver cancer using TCGA dataset through the SurvExpress web and confirmed *GPR50* overexpression ([Figure 1](#fig1){ref-type="fig"}D). We then examined mutation and copy number alterations (CNAs) in the liver cancer TCGA dataset through the cBioPortal web and found that approximately 3% of the samples showed mutation, amplification, deep deletion, or mRNA upregulation of *GPR50* genes ([Figure 1](#fig1){ref-type="fig"}E). Moreover, we checked *GPR50* mRNA and protein expression levels in the normal hepatocyte cell line MIHA and several HCC cell lines, including HepG2, SNU449, and SNU475, via reverse-transcriptase PCR (RT-PCR) and western blot analyses and found that *GPR50* expression was clearly overexpressed in the HCC cell lines ([Figure 1](#fig1){ref-type="fig"}F). Overall, these results indicate that *GPR50* expression is dysregulated in various cancers and specifically upregulated in HCC.

*GPR50* Knockdown Decreases Cell Proliferation, Migration, Sphere Formation, and Drug Resistance {#sec2.2}
------------------------------------------------------------------------------------------------

To examine the role of *GPR50* in HCC, we knocked down *GPR50* using GPR50-targeted short hairpin RNA (shRNA) in two HCC cell lines: HepG2 and SNU475. *GPR50* knockdown was confirmed (approximately 95%) via RT-PCR and western blot analysis ([Figure 2](#fig2){ref-type="fig"}A). We found that cell proliferation was decreased upon *GPR50* silencing in both HepG2 and SNU475 cells ([Figure 2](#fig2){ref-type="fig"}B). In addition, cell migration, sphere formation, and drug resistance ([Figures 2](#fig2){ref-type="fig"}C, 2D, and 2F) were attenuated in GPR50-knockdown HepG2 and SNU475 cells compared with their normal counterparts. We also found that expression of stemness markers, such as *NANOG*, *SOX2*, *OCT4*, and *KLF4*, and drug-resistance markers, such as *P-GP*, *ABCG2*, *ABCC1*, *ALDH1A1*, and *ABCB5*, was decreased upon *GPR50* knockdown ([Figures 2](#fig2){ref-type="fig"}E and 2G; [Figure S1](#mmc1){ref-type="supplementary-material"}), suggesting that *GPR50* has oncogenic ability and regulates HCC progression.Figure 2*GPR50* Knockdown Led to Suppressed Cancer Properties in HCC(A) GPR50 expression in scramble and shGPR50-transduced cells was analyzed by RT-PCR and western blotting in the indicated cancer cell lines. *GAPDH*/actin was used as a loading control. (B) Cell proliferation was analyzed using trypan blue. Cells were counted over 5 days. (C) Wound-healing assay to test migration of the indicated cells. Cell migration was observed at the indicated time points and presented as percentage (%) wound enclosure (right panel). Photos were acquired using inverted light microscopy. (D) Cell-sphere formation assay was performed using noncoated culture dishes. Spheres were counted after 5 days of culture with crystal violet staining and presented as the percent (%) of colonies. Photos were acquired by inverted light microscopy. (E) mRNA expression of stemness markers was analyzed by RT-PCR. *GAPDH* was used as an internal standard. (F) Effect of *GPR50* knockdown on drug resistance was measured by cell counting after 48 h of doxorubicin (DOX) treatment (0.5 μM). (G) mRNA expression levels of drug-resistance marker genes were analyzed by RT-PCR using GPR50-knockdown cells. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001, ∗∗∗∗p \< 0.0001.

*GPR50* Is a Novel Regulator of the Notch Signaling Pathway {#sec2.3}
-----------------------------------------------------------

As *GPR50* knockdown attenuated cancer progression, we attempted to uncover the underlying signaling mechanism. For that, we checked several signaling pathways that potentially contribute to cancer progression. We found that expression of *HES1*, a Notch signaling target gene, was significantly downregulated upon *GPR50* knockdown ([Figure 3](#fig3){ref-type="fig"}A). We did not detect any significant differences in the expression of target genes of other signaling pathways, including Wnt, Hedgehog, and Hippo, which are predominantly involved in cancer progression, stemness, and metastasis.[@bib29], [@bib30], [@bib31], [@bib32], [@bib33] Expression of other Notch pathway target genes, such as *NOTCH1*, *MAML1*, and *RBPjK*, was also suppressed upon *GPR50* knockdown in HCC cells ([Figure 3](#fig3){ref-type="fig"}B). Western blotting confirmed the reduced protein expression levels of Notch intracellular domain (NICD) and HES1 upon *GPR50* knockdown ([Figure 3](#fig3){ref-type="fig"}C). Moreover, transcription activity of *HES1* and *HES5* was reduced upon *GPR50* silencing ([Figures 3](#fig3){ref-type="fig"}D and 3E).Figure 3Silencing of *GPR50* Expression Downregulates Notch Signaling in HCC Cell Lines(A) mRNA expression levels of different signaling target genes (*DKK1* for Wnt signaling, *HES1* for Notch signaling, *GL1* for Hedgehog signaling, and *YAP1* for Hippo signaling) were analyzed using qRT-PCR and normalized to that of *GAPDH.* (B) mRNA expression levels of *NOTCH1*, *MAML1*, *RBPjK*, and *HES1* were analyzed using RT-PCR; *GAPDH* was used as an internal standard. (C) Protein levels of NICD and HES1 were assessed using western blotting; actin was used as a loading control. (D and E) Notch signaling transcriptional activity was analyzed using *HES1* (D) and *HES5* (E) luciferase assays. (F) Overexpression of FLAG-NICD was confirmed by western blot analysis using FLAG antibody; actin was used as a loading control. (G and H) Fold change of Notch signaling transcriptional activity was analyzed after overexpression of NICD in the indicated cells using *HES1* (G) and *HES5* (H) luciferase assays. (I and J) Cell viability (I) and sphere formation (J) were analyzed after overexpression of NICD in the indicated cells. ns, no significance; ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001, ∗∗∗∗p \< 0.0001.

Next, we induced the Notch signaling pathway in *GPR50*-knockdown cells using NICD to test whether NICD overexpression can relieve *GPR50* suppression effects. FLAG-NICD overexpression in SNU475 cells was confirmed by western blot analysis using a FLAG antibody ([Figure 3](#fig3){ref-type="fig"}F). We then analyzed *HES1* and *HES5* promoter activity and found that the shGPR50-induced reduction in *HES1* and *HES5* transcriptional activity was increased upon NICD overexpression ([Figures 3](#fig3){ref-type="fig"}G and 3H). Moreover, shGPR50-induced reduction in cell viability and sphere formation was also reversed upon NICD overexpression ([Figures 3](#fig3){ref-type="fig"}I and 3J). These results indicate that attenuation of HCC progression via shGPR50 can be regulated through the Notch signaling pathway.

The *GPR50*-Regulated Notch Signaling Pathway Is Notch Ligand Independent {#sec2.4}
-------------------------------------------------------------------------

We further assessed the Notch ligand dependency of the *GPR50*-regulated Notch signaling pathway, because this pathway can be regulated in a ligand-dependent[@bib34], [@bib35], [@bib36] or -independent[@bib37] manner. First, we focused on ligand-dependent Notch signaling activation upon *GPR50* knockdown. mRNA expression of the Notch signaling ligands Jagged 1 (*JAG1*) and 2, as well as delta-like ligand 1 (*DLL1*), 3, and 4, was not significantly altered in shGPR50-HepG2 and SNU475 cells compared with their normal counterparts ([Figure 4](#fig4){ref-type="fig"}A). To confirm, we overexpressed *JAG1* and *DLL1* in scramble and shGPR50-SNU475 cells, validated by RT-PCR ([Figures 4](#fig4){ref-type="fig"}B and 4C), and found that Notch ligand overexpression did not significantly affect the shGPR50-induced reduction in *HES1* mRNA expression, cell viability, and sphere formation ([Figures 4](#fig4){ref-type="fig"}D--4F). Taken together, these results indicate that suppression of Notch signaling via *GPR50* knockdown occurs in a ligand-independent manner.Figure 4GPR50 Does Not Regulate the Ligand-Dependent Notch Signaling Pathway(A) mRNA expression levels of the Notch ligands Jagged 1 and 2 (*JAG1* and *JAG2*) and Delta-like 1, 3, and 4 (*DLL1*, *DLL3*, and *DLL4*) were analyzed using real-time RT-PCR and normalized to that of *GAPDH.* (B and C) *JAG1* (B) and *DLL1* (C) overexpression was confirmed by real-time RT-PCR and normalized to that of *GAPDH.* (D--F) *HES1* mRNA expression (D), cell viability (E), and sphere formation (F) were analyzed after overexpression of *JAG1* and *DLL1* in the indicated cells. ns, no significance; ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001, ∗∗∗∗p \< 0.0001.

*GPR50* Regulates *ADAM17* Transcription through the AKT/SP1 Axis {#sec2.5}
-----------------------------------------------------------------

Next, we investigated the ligand-independent activation of Notch signaling by analyzing mRNA expression levels of ADAM metallopeptidases, including *ADAM9*, -*10*, -*12*, and -*17*, which have been reported to regulate the Notch signaling pathway.[@bib37], [@bib38], [@bib39], [@bib40], [@bib41] Among these ADAMs, *ADAM17* mRNA expression was significantly downregulated upon *GPR50* knockdown in both HCC cell lines, HepG2 and SNU475 ([Figure 5](#fig5){ref-type="fig"}A). Moreover, we analyzed the correlation between *ADAMs* and *GPR50* mRNA expression in HCC using TCGA database through the cBioPortal web and found that mRNA expression levels of the studied *ADAMs* were positively correlated with *GPR50* expression, with *ADAM17* showing the most significant correlation ([Figure S2](#mmc1){ref-type="supplementary-material"}).Figure 5GPR50 Regulates *ADAM17* Transcription via the AKT/SP1 Axis(A) Expression levels of Notch signaling regulating genes *ADAM9*, *ADAM10*, *ADAM12*, and *ADAM17* were analyzed using qRT-PCR; *GAPDH* was used as an internal standard. (B) Protein expression levels of AKT, phosphorylated (p)-AKT, GSK3β, p-GSK3β, ERK, p-ERK, p38, and p-p38 were analyzed using western blotting; actin was used as a loading control. (C) Scramble and shGPR50-HepG2 cells were treated with/without LY294002 (20 μM), and then protein levels of PI3K, AKT, p-AKT, GSK3β, and p-GSK3β were assessed by western blotting; actin was used as a loading control. (D) Scramble and shGPR50-HepG2 cells were treated with LY294002 (20 μM), and then mRNA expression levels of *SP1*, *SP2*, *SP3*, and *SP4* were analyzed using qRT-PCR and normalized to that of *GAPDH*. (E and F) Scramble and shGPR50-HepG2 cells were treated with LY294002 (20 μM), and then cell viability (E) and wound healing (F) were analyzed at the indicated time points. (G) Scramble and shGPR50-HepG2 cells were treated with LY294002 (20 μM) in the presence of DOX (0.5 μM), and then drug resistance was measured by cell counting after 48 h. (H) Scramble and shGPR50-HepG2 cells were treated with LY294002 (20 μM), and then a sphere-formation assay was performed using the noncoated culture dishes. Spheres were counted after 5 days of culture using crystal violet staining and represented as the percent (%) of colonies. (I) Scramble and shGPR50-HepG2 cells were treated with LY294002 (20 μM) and then mRNA expression levels of *ADAM9*, *ADAM10*, *ADAM12*, and *ADAM17* were analyzed using qRT-PCR and normalized to that of *GAPDH*. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001, ∗∗∗∗p \< 0.0001.

Therefore, we aimed to uncover how GPR50 regulates *ADAM17* transcription by examining whether *GPR50* knockdown affects the AKT, extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK), and p38/MAPK signaling pathways, as previous studies reported that transcription of *ADAM17* can be regulated through these pathways.[@bib42], [@bib43], [@bib44] We found that AKT phosphorylation was downregulated in shGPR50-HepG2 cells compared with that in scramble-HepG2 cells, whereas the ERK/MAPK and p38/MAPK signaling pathways were not altered upon *GPR50* knockdown ([Figure 5](#fig5){ref-type="fig"}B). Glycogen synthase kinase 3β (GSK3β phosphorylation at Ser9 was also altered upon *GPR50* suppression ([Figure 5](#fig5){ref-type="fig"}B). To confirm these findings, we treated *GPR50*-knockdown cells with the AKT inhibitor LY294002 (20 μM).[@bib45] LY294002 treatment drastically reduced AKT phosphorylation in *GPR50*-knockdown cells compared with control cells ([Figure 5](#fig5){ref-type="fig"}C). LY294002 treatment also induced GSK3β phosphorylation in sh*GPR50* cells compared with that in control cells ([Figure 5](#fig5){ref-type="fig"}C), which may subsequently regulate other signaling pathways, including GSK3β/mammalian target of rapamycin (mTOR) or Wnt/β-catenin, which are yet to be investigated.

As the *ADAM17* promoter region contains a high guanine-cytosine (GC)-rich sequence that was depicted to bind various transcription factors, including SP1,[@bib46]^,^[@bib47] we tested whether *GPR50* silencing regulates *SP1* expression. We examined the mRNA expression levels of all SP family genes (*SP1*, -*2*, -*3*, and -*4*) and found that *SP1* expression was significantly downregulated upon *GPR50* suppression ([Figure 5](#fig5){ref-type="fig"}D). Moreover, *SP1* expression was significantly attenuated upon LY294002 treatment in *GPR50*-knockdown cells compared with that in control cells ([Figure 5](#fig5){ref-type="fig"}D). Cell proliferation, wound healing/migration, drug resistance, and sphere formation ([Figures 5](#fig5){ref-type="fig"}E--5H) were also widely attenuated upon LY294002 treatment. We also analyzed ADAM expression and found that *ADAM17* was significantly downregulated upon LY294002 treatment in *GPR50*-silenced cells compared with that in control cells ([Figure 5](#fig5){ref-type="fig"}I). Thus, these results support the notion that *GPR50* knockdown mediates *ADAM17* downregulation through the AKT/SP1 axis.

GPR50 Directly Interacts with ADAM17 and Regulates ADAM17 Activity {#sec2.6}
------------------------------------------------------------------

As *GPR50* knockdown suppressed *ADAM17* transcription, we analyzed ADAM17 protein levels upon *GPR50* silencing and found that ADAM17 protein levels were attenuated in sh*GPR50* cells ([Figure 6](#fig6){ref-type="fig"}A). ADAM17 is a proteolytic enzyme that can cleave Notch receptors and subsequently activate the Notch signaling pathway.[@bib48] Thus, we examined ADAM17 activity in *GPR50*-knockdown cells and found reduced ADAM17 activity ([Figure 6](#fig6){ref-type="fig"}B). We theorized that GPR50 and ADAM17 can directly interact with each other (as both are cell membrane proteins), which was confirmed via coimmunoprecipitation (coIP; [Figure 6](#fig6){ref-type="fig"}C), indicating that ligand-independent Notch signaling activation is mediated through the GPR50-ADAM17 interaction.Figure 6GPR50 Directly Interacts with ADAM17 and Activates the Ligand-Independent Notch Signaling Pathway via ADAM17 in HCC(A) Protein expression levels of ADAM17 were analyzed using western blotting; actin was used as a loading control. (B) Fold change in ADAM17 activity was analyzed using the ADAM17 ELISA assay. (C) Lysates from the indicated cells were used for immunoprecipitation using Protein A/G Sepharose, as well as antibodies specific for GPR50, ADAM17, and normal IgG. The immunoprecipitates were analyzed by western blotting with the indicated antibodies. For inputs, lysates were analyzed by western blotting with the indicated antibodies. (D) Overexpression of FLAG-*ADAM17* was confirmed by western blot analysis using FLAG antibody; actin was used as a loading control. (E and F) Fold change in Notch signaling transcriptional activity was analyzed using *HES1* (E) and *HES5* (F) luciferase assays after overexpression of *ADAM17* and treatment with/without marimastat (4 μM). (G) Fold change in ADAM17 enzymatic activity was analyzed using the ADAM17 ELISA assay after overexpression of ADAM17 and treatment with/without marimastat (4 μM). (H) Cell viability was analyzed using the EZ-cytox 4-\[3-(4iodophenyl)-2-(4- nitrophenyl)-2H-5-tetrazolio\]-1,3-benzene disulfonate (WST-1) assay after overexpression of ADAM17 and treatment with/without marimastat (4 μM) after 24 h. (I) Sphere formation assay was performed using the noncoated culture dishes after overexpression of ADAM17 and treatment with/without marimastat (4 μM). Spheres were counted after 5 days of culture using crystal violet staining and presented as fold change in colonies. ns, no significance; ∗∗p \< 0.01, ∗∗∗∗p \< 0.0001.

Overexpression of *ADAM17* Relieves *GPR50*-Knockdown Effects {#sec2.7}
-------------------------------------------------------------

We next overexpressed ADAM17 in *GPR50*-knockdown SNU475 cells to test whether *ADAM17* overexpression can relieve the effects of shGPR50. Overexpression of FLAG-*ADAM17* was confirmed by western blot analysis using a FLAG antibody ([Figure 6](#fig6){ref-type="fig"}D). Afterward, Notch signaling activation upon *ADAM17* overexpression in *GPR50*-knockdown cells was analyzed by examining *HES1* and *HES5* transcription activity via luciferase assays ([Figures 6](#fig6){ref-type="fig"}E and 6F). shGPR50-induced suppression of *HES1* and *HES5* transcription activity was reversed upon *ADAM17* overexpression ([Figures 6](#fig6){ref-type="fig"}E and 6F). Moreover, treatment with marimastat (4 μM),[@bib49] an ADAM17 inhibitor, suppressed the effects of *ADAM17* overexpression specially in shGPR50-SNU475 cells ([Figures 6](#fig6){ref-type="fig"}E and 6F). Similarly, shGPR50-induced reduction in ADAM17 activity was relieved upon *ADAM17* overexpression in SNU475 cells; conversely, marimastat (4 μM) treatment of *ADAM17*-overexpressed SNU475 cells reduced ADAM17 activity, which was marked in shGPR50-SNU475 cells ([Figure 6](#fig6){ref-type="fig"}G). Moreover, the shGPR50-induced reduction in cell viability ([Figure 6](#fig6){ref-type="fig"}H) and sphere formation ([Figure 6](#fig6){ref-type="fig"}I) was rescued upon *ADAM17* overexpression in SNU475 cells, whereas marimastat alone or marimastat + shGPR50 suppressed the effects of *ADAM17* overexpression in SNU475 cells. These results indicate that the shGPR50-induced suppression of HCC progression is mediated through ADAM17-dependent Notch signaling suppression.

Overexpression of *GPR50* Induces Cancer Progression through ADAM17-Dependent Notch Signaling Pathway Activation {#sec2.8}
----------------------------------------------------------------------------------------------------------------

Finally, we assessed the role of the ADAM17-activated Notch signaling pathway during *GPR50* overexpression in HCC. We first confirmed *GPR50* overexpression in the MIHA and HepG2 cell lines using RT-PCR and western blot analysis ([Figure 7](#fig7){ref-type="fig"}A) and then analyzed the effect of *GPR50* overexpression in MIHA and HepG2 cells. Cell viability was found significantly increased in both MIHA and HepG2 cells upon *GPR50* overexpression ([Figure 7](#fig7){ref-type="fig"}B); similarly, colony-formation capability was also significantly induced ([Figure 7](#fig7){ref-type="fig"}C). Next, we evaluated whether *GPR50* overexpression upregulates ADAM17 and the expression of Notch signaling-responsive proteins, such as NICD and HES1. Expectedly, ADAM17, NICD, and HES1 protein levels were upregulated upon *GPR50* overexpression in MIHA and HepG2 cells ([Figure 7](#fig7){ref-type="fig"}D). Subsequently, transcriptional activity of the Notch target genes *HES1* and *HES5* was significantly enhanced upon *GPR50* overexpression in both MIHA and HepG2 cells ([Figures 7](#fig7){ref-type="fig"}E and 7F). Moreover, ADAM17 activity upon *GPR50* overexpression in HepG2 cells was significantly augmented compared with that of control HepG2 cells ([Figure 7](#fig7){ref-type="fig"}G).Figure 7Overexpression of *GPR50* Augments Notch Signaling via the Ligand-Independent ADAM17 Axis in HCC Cells(A) *GPR50* overexpression was confirmed by RT-PCR and western blot analysis and normalized to that of *GAPDH* or actin. (B) Cell viability was analyzed over 3 days after overexpression of *GPR50* using the EZ-cytox WST-1 assay. (C) Cell-sphere formation assay was performed using the noncoated culture dishes after *GPR50* overexpression. Spheres were counted after 5 days of culture using crystal violet staining and presented as the percent (%) of colonies. Photos were acquired by inverted light microscopy. (D) Protein expression levels of ADAM17, NICD, and HES1 were analyzed by western blot analysis after *GPR50* overexpression. (E and F) Notch signaling transcriptional activity was analyzed after *GPR50* overexpression using the *HES1* (E) and *HES5* (F) luciferase assays. (G) Fold change in ADAM17 enzymatic activity was analyzed using the ADAM17 ELISA assay after *GPR50* overexpression. (H) Protein expression levels of GPR50, ADAM17, NICD, and HES1 were analyzed by western blot analysis after *GPR50* overexpression and treatment with/without DAPT (Notch signaling inhibitor) and/or marimastat (ADAM17 inhibitor). (I) Fold change in ADAM17 activity was analyzed using the ADAM17 ELISA assay after *GPR50* overexpression and treatment with/without DAPT and/or marimastat. (J and K) Notch signaling transcriptional activity was analyzed after *GPR50* overexpression and treatment with/without DAPT and/or marimastat using the *HES1* (J) and *HES5* (K) luciferase assay. ns, no significance; ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001, ∗∗∗∗p \< 0.0001.

To confirm the GPR50-induced regulation of the Notch signaling pathway through ADAM17, we treated GPR50-overexpressed HepG2 cells with marimastat (4 μM) and/or the Notch signaling (γ-secretase) inhibitor DAPT (20 μM).[@bib50] GPR50 protein expression was not significantly altered upon marimastat and/or DAPT treatment in *GPR50*-overexpressed HepG2 cells, whereas the *GPR50* overexpression-induced upregulation of ADAM17, NICD, and HES1 was dramatically relieved upon marimastat and/or DAPT treatment ([Figure 7](#fig7){ref-type="fig"}H). Moreover, the *GPR50* overexpression-induced ADAM17 activity was significantly attenuated upon marimastat treatment ([Figure 7](#fig7){ref-type="fig"}I), whereas enhanced *HES1* and *HES5* transcriptional activity was significantly relieved upon treatment with marimastat and/or DAPT in HepG2 cells ([Figures 7](#fig7){ref-type="fig"}J and 7K). These results strongly suggest that GPR50 regulates HCC progression through the ADAM17-mediated Notch signaling pathway.

Discussion {#sec3}
==========

An orphan GPCR (GPR50) was shown to regulate bipolar-affective disorder, lipid metabolism, thermogenesis, adipogenesis, and neuronal development,[@bib21], [@bib22], [@bib23], [@bib24], [@bib25] although it has been claimed that GPR50 has high sequence similarity with melatonin receptors (MT1 and MT2), but melatonin does not bind to GPR50.[@bib19]^,^[@bib20] GPR50 was also reported to interact directly with various proteins, such as TIP60, NOGO-A, MT1, and MT2, via heterodimerization through the large carboxyl-terminal tail (C-tail) of GPR50.[@bib24]^,^[@bib51]^,^[@bib52] Moreover, previous studies displayed that GPR50 can directly interact with transforming growth factor-β1 (TGF-β1) and constitutively activate the canonical SMAD2/3 signaling pathway, which contributes to regulation of breast cancer progression, indicating that GPR50 can act as a tumor suppressor in breast cancer.[@bib27]^,^[@bib28] In addition, our previous study was given a clue that several GPCRs, including GPR50, are involved in the reprogramming of somatic cells to cancer stem cells and in the maintenance of stemness function.[@bib26] However, little is known regarding the biological significance of GPR50 in liver cancer.

Here, we investigated the expression patterns of GPR50 in various cancer cells and found dysregulated GRP50 expression. Moreover, GPR50 expression was lower in normal hepatocytes than in HCC cells. We also found that *GPR50* knockdown attenuates cell proliferation, sphere formation, migration, and drug resistance of HCC cells, whereas overexpression of *GPR50* upregulates cancer properties in hepatocytes (see [Figures 2](#fig2){ref-type="fig"} and [7](#fig7){ref-type="fig"}), strongly supporting an oncogenic function for GPR50 in HCCs. We further investigated the underlying molecular mechanisms of GPR50-mediated HCC regulation and found that GPR50 regulates HCC cell proliferation, migration, sphere formation, and drug resistance via the Notch signaling pathway. We identified, for the first time, a novel GPR50-mediated Notch signaling activation pathway that is activated in a ligand-independent manner.

Notch signaling is involved in most multicellular processes in cancer cells, including cell fate, proliferation, metastasis, invasion, and stemness.[@bib53], [@bib54], [@bib55], [@bib56], [@bib57] Recent studies have depicted that the Notch signaling pathway can play either pro-oncogenic or tumor-suppressive roles in cancer cells.[@bib58], [@bib59], [@bib60] Notch signaling is normally triggered by a Notch-activating ligand that is subsequently processed through two proteolytic cleavage events via ADAM17 and the γ-secretase complex.[@bib48] This cleavage can then result in release of the NICD, which is imported to the nucleus and binds to cotranscription factors, including MAML1, RBP-J, p300, and CSL, to trigger expression of Notch signaling target genes.[@bib53]^,^[@bib54] Notably, the Notch signaling pathway is significantly associated with liver cirrhosis and HCC.[@bib61] Although various members of the Notch signaling pathway may act as inhibitors or enhancers of HCC, the Notch signaling pathway generally plays a carcinogenic role in HCC, and activation of Notch signaling has been associated with a more malignant phenotype.[@bib62] Therefore, identification of reliable Notch pathway regulatory mechanisms is critical for the application of Notch-based HCC therapeutic strategies, as regulation of the Notch pathway can potentially suppress HCC progression and aggressiveness.

We further found that the GPR50-regulated Notch signaling pathway is mediated by ADAM17, independent from the Notch ligands JAG and DLL. ADAM, a single-pass transmembrane protein, is involved in multiple cellular functions, such as migration, proteolysis of extracellular matrix (ECM) components, and shedding of membrane proteins (e.g., cytokines and growth factors); fertilization; development; inflammation; asthma; and neurodegenerative diseases, such as Alzheimer's disease.[@bib63], [@bib64], [@bib65] Several ADAM family proteins have been identified and are characterized by their domain organization, including a pro-domain; a metalloprotease, disintegrin, cysteine-rich, epidermal growth factor (EGF)-like domain; and transmembrane domains, and a C-terminal cytoplasmic tail. Several reports have demonstrated that ADAMs play an important role in HCC pathogenesis.[@bib66] ADAM17, also known as TACE (tumor necrosis factor α \[TNF-α\]-converting-enzyme), has been reported to be a Notch receptor molecular scissor, which leads to tumorigenesis and tumor progression.[@bib67]^,^[@bib68] Moreover, ADAM17 activates the Notch signaling pathway in a ligand-independent manner[@bib37] and is reported to regulate cell proliferation, angiogenesis, invasion, and apoptosis of cancer cells by regulating Notch signaling.[@bib38]^,^[@bib39]^,^[@bib69] However, ligand-independent Notch signaling activation via ADAM17 is not fully elucidated.

Consistent with our results, a number of studies depicted that ligand-independent Notch activation is mediated by ADAM17.[@bib37]^,^[@bib70] Another study demonstrated Notch signaling activation without cell-cell contact in the presence of soluble JAG1.[@bib34] Moreover, a study demonstrated that several GPCRs, including orphan GPCRs, resulted in ADAM17 activation and subsequently induced TGF-α shedding in HEK293 cells.[@bib71] Furthermore, GPCRs, including GPR50, were reported to interact with other receptors from the same family or different receptor and transporter proteins through heterodimerization, eventually forming molecular complexes.[@bib24]^,^[@bib52]^,^[@bib72] Similarly, our findings demonstrated that GPR50 can form a molecular complex with ADAM17 through direct interaction in HCC (see [Figure 6](#fig6){ref-type="fig"}C), which subsequently activates Notch signaling via ADAM17 activity, strongly supporting a novel signaling pathway between GPR50 and the ligand-independent, ADAM17-mediated Notch signaling.

We further demonstrated that GPR50 can regulate ADAM17 transcription and translation through the AKT/SP1 signaling axis, which is in agreement with previous studies that ADAM17 can be transcriptionally regulated via the AKT, ERK/MAPK, and p38/MAPK signaling pathways.[@bib42], [@bib43], [@bib44] Moreover, the ADAM17 promoter has a high GC-rich sequence where a number of transcription factors, including SP1, can bind.[@bib46]^,^[@bib47] SP1 has been shown to have a potential role in cancer by regulating the transcription of several genes that have high GC-rich sequences in their DNA-binding promoter regions.[@bib73], [@bib74], [@bib75], [@bib76] SP1 is regulated by its upstream effectors, including the phosphatidylinositol 3-kinase (PI3K)/AKT, ERK, and p38/MAPK signaling pathways.[@bib77], [@bib78], [@bib79], [@bib80] Moreover, a study demonstrated that GPCRs can regulate SP1 via their downstream proteins and effectors (i.e., β-arrestin 1), which represses leukemic cell senescence.[@bib81] Therefore, by taking into consideration these previous studies and our findings, there is ample evidence supporting GPR50-mediated ADAM17 transcription and translation via the AKT/SP1 axis.

In conclusion, we demonstrated how the orphan receptor GPR50 regulates the ligand-independent activation of Notch signaling through GPR50-mediated modulation of ADAM17 activity in HCC ([Figure 8](#fig8){ref-type="fig"}). A signaling cascade initiating from GPR50 was uncovered, wherein GPR50 was also found to regulate ADAM17 transcription and translation via the AKT/SP1 axis in HCC ([Figure 8](#fig8){ref-type="fig"}). Thus, our findings revealed the molecular basis underlying the GPR50 and ADAM17 complex-mediated, ligand-independent modulation of the Notch signaling pathway, which can be exploited in Notch-based HCC therapeutic strategies.Figure 8Schematic Diagram Illustrating GPR50 Function in the Notch Signaling Pathway in HCCGPR50 regulates *ADAM17* transcription via the AKT/SP1 axis and directly interacts with ADAM17 to induce ADAM17 enzymatic activity, which subsequently activates ligand-independent Notch signaling, mediating HCC progression.

Materials and Methods {#sec4}
=====================

Bioinformatic Analysis {#sec4.1}
----------------------

The expected expression levels of the *GPR50* gene in various cancers were retrieved from the Oncomine database (<https://www.oncomine.org/resource/login.html>).[@bib82]^,^[@bib83] Fold changes in mRNA expression in cancer tissues compared with their normal counterparts were acquired using a default threshold. Gene expression was also analyzed using GEO, a web database that gathers submitted high-throughput gene-expression data of chips, microarray, or next-genome sequencing (<https://www.ncbi.nlm.nih.gov/geo/>).[@bib84] Microarray datasets with accession numbers GEO: GSE1477, GSE7803, GSE20347, GSE45436, and GSE2514 containing gene-expression information of clinical human BRC, CEC, ESC, HCC, and LUC patients, respectively, were used in this study. The other GEO datasets are listed in [Table S1](#mmc1){ref-type="supplementary-material"}. The raw data were retrieved and replotted using GraphPad Prism 7 software (GraphPad Software, La Jolla, CA, USA).

With the use of a web-based tool for survival analysis, SurvExpress (<http://bioinformatica.mty.itesm.mx:8080/Biomatec/SurvivaX.jsp>),[@bib85] we conducted an integrative analysis of *GPR50* mRNA expression levels and clinical outcomes. This database contains more than 39,000 samples and 225 datasets covering tumors from more than 26 different tissues. With the use of this platform, survival plots were generated for GPR50 in specific cancer types using TCGA data. We further performed an integrative analysis of GPR50 and clinical characteristics using cBioPortal, an open-access resource found at <http://www.cbioportal.org/>,[@bib86]^,^[@bib87] which currently provides access to data from more than 48,668 tumor samples and 172 cancer studies in TCGA pipeline. The query interface, combined with customized data storage, enabled us to explore genetic alterations interactively across samples curated from national and international cancer studies for specific genes. The primary search parameters included alterations (amplification, deep deletion, and missense mutations), CNAs, gene-gene correlation from Genomic Identification of Significant Targets in Cancer (GISTIC), and RNA-seq data using the default settings.

Cell Culture {#sec4.2}
------------

The human HCC cell lines (HepG2, SNU449, and SNU475; American Type Culture Collection \[ATCC\], Manassas, VA, USA) and the normal hepatocyte cell line MIHA (ATCC) were cultured in DMEM (for MIHA and HepG2 cell lines; Sigma-Aldrich, St. Louis, MO, USA) or RPMI 1640 (for SNU449 and SNU475 cell lines; Sigma-Aldrich), supplemented with 10% heat-inactivated fetal bovine serum (FBS; GE Healthcare HyClone, Pittsburgh, PA, USA), 100 U/mL penicillin (GE Healthcare HyClone), and 100 mg/mL streptomycin (GE Healthcare HyClone). Cells were cultured at 37°C in a humidified atmosphere of 5% CO~2~. All cell lines were tested for possible mycoplasma contamination using the *BioMycoX* Mycoplasma PCR Detection Kit (CS-D-25; Cellsafe, Suwon, Republic of Korea) and were authenticated using short tandem repeat (STR) profiling.

*GPR50* Knockdown Using shRNA Constructs {#sec4.3}
----------------------------------------

Sense and antisense oligonucleotides were synthesized for control (scramble) or *GPR50* knockdown (shGPR50-1 and -2); the sequences are listed in [Table S2](#mmc1){ref-type="supplementary-material"}. The oligonucleotides were then annealed and cloned into a pGreenPuro lentiviral vector (System Biosciences, Mountain View, CA, USA) containing *Bam*HI and *Eco*RI restriction enzyme sites, according to the manufacturer's instructions. Briefly, two oligonucleotides were annealed at 95°C for 2 min in a heat block with annealing buffer, and then the samples were left to cool down to room temperature. The annealed, double-stranded DNA was then ligated into a lentiviral vector using the T4 DNA ligase enzyme (Promega, Madison, WI, USA). Sequences of the newly constructed plasmids were confirmed by sequencing analysis.

Overexpression of *GPR50*, *JAG1*, *DLL1*, *NICD*, and *ADAM17* {#sec4.4}
---------------------------------------------------------------

For overexpression of *GPR50*, the pGEM-T Easy vector (Promega) was used to clone the complete GPR50 coding sequence using the primers listed in [Table S2](#mmc1){ref-type="supplementary-material"}. Afterward, the complete coding sequence (without the termination codon) was further subcloned into the pCDH-EF1-MCS-T2A-copGFP lentiviral vector (System Biosciences) using *Xba*I and *Eco*RI restriction enzymes and the primers listed in [Table S2](#mmc1){ref-type="supplementary-material"}.

For overexpression of *JAG1*, *DLL1*, *NICD*, and *ADAM17*, cells were incubated overnight to a cell density of 2 × 10^5^ cells per well in a 24-well culture plate. The cells were then transfected with the expression vectors for hemagglutinin (HA)-*JAG1*, GFP-*DLL1*, FLAG-*NICD* (kind gifts from Professor Hee-Sae Park, Chonnam National University, Republic of Korea), and FLAG-*ADAM17* (plasmid number 31713; Addgene, Watertown, MA, USA)[@bib88] using the HyliMax transfection reagent in a 1:3 ratio (Dojindo, Kumamoto, Japan), according to manufacturer's instructions. After 48 h of transfection, the transfected cells were ready for use in further experiments.

Lentivirus Production and Transduction {#sec4.5}
--------------------------------------

To generate the lentivirus, the Rev response element (RRE)/REV lentivirus expressing system[@bib89] was used. Briefly, 60%--70% confluent HEK293T cells were cultured in 100 mm dishes on the day of transfection using the calcium phosphate transfection method. The medium was replaced with fresh medium and plasmids (RRE, REV, and target), after which, the calcium phosphate mixture was added dropwise into the dishes. After 12--16 h, the medium containing the plasmids was removed, and the cells were washed once with PBS. Then, an equal amount of medium was added. After 48 h, the cell supernatant (virus soup) was collected and filtered through a 0.45-μm pore capsule and used for infection, as previously described.[@bib90] Virus titers were also quantified as previously described.[@bib91] For virus infection, we used ∼8.0 × 10^8^ IU/mL viral particles for stable knockdown in the indicated cells. All experiments were started 72 h postinfection.[@bib92]

RNA Extraction and Quantitative RT-PCR (qRT-PCR) {#sec4.6}
------------------------------------------------

Total RNA was extracted using an Easy-Blue RNA Extraction Kit (iNtRON Biotechnology, Seongnam, Republic of Korea), and the purified total RNA (2 μg) was reverse transcribed into cDNA using a cDNA synthesis kit (Promega), according to the manufacturer's instructions. For PCR analysis, 1 μL of synthesized cDNA, specific forward and reverse primers, and r-Taq Plus Master Mix (Elpis Biotech, Daejeon, Republic of Korea) were mixed and analyzed by thermocycler PCR, after which, the PCR products were analyzed by agarose gel electrophoresis. DNA was stained via ethidium bromide (EtBr), observed under UV light, and imaged. The images were then analyzed in Photoshop CS6 (Adobe, Mountain View, CA, USA), and the relative expression fold changes were measured using ImageJ; the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*) was used as a loading control, as described previously.[@bib90] qRT-PCR was performed using a thermal cycler (PTC-200) with a Chromo4 optical detector (MJ Research; Bio-Rad Laboratories, Hercules, CA, USA) using Fast 2X SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA); *GAPDH* was used as an internal control, as described previously.[@bib93] The primers used are listed in [Table S3](#mmc1){ref-type="supplementary-material"}.

Western Blotting {#sec4.7}
----------------

Total cell lysates were extracted from the indicated cells using lysis buffer. The cell lysates were then incubated at 4°C for 15 min, vortexed every 2--3 min, and centrifuged at 16,600 × *g* for 15 min. Afterward, concentrations of the extracted proteins were measured using a Bradford assay kit (Bio-Rad Laboratories). Protein samples (40--60 μg) were then loaded onto either 10% or 12% SDS-PAGE gels and electrophoresed, after which, the proteins were transferred to nitrocellulose blotting membranes. The membranes were blocked with 5% skim milk for 1 h and subsequently incubated with primary antibodies against GPR50 (\#14032S, 1:1,000; Cell Signaling Technology, Danvers, MA, USA), NANOG (SC-293121, 1:200; Santa Cruz Biotechnology, Dallas, TX, USA), OCT4 (SC-9081, 1:200; Santa Cruz Biotechnology), ABCG2 (SC-377176, 1:1,000; Santa Cruz Biotechnology), phospho-p38 (\#9211S, 1:1,000; Cell Signaling Technology), NICD (ab83232, 1:1,000; Abcam, Cambridge, UK), FLAG (F3165, 1:2,000; Sigma-Aldrich), PI3K (SC1637, 1:1,000; Santa Cruz Biotechnology), AKT (SC-1619, 1:1,000; Santa Cruz Biotechnology), phospho-AKT (SC-16646-R, 1:1,000; Santa Cruz Biotechnology), ERK (SC-153, 1:1,000; Santa Cruz Biotechnology), phospho-ERK (SC-7383, 1:1,000; Santa Cruz Biotechnology), p38 (SC-7149, 1:1,000; Santa Cruz Biotechnology), GSK3β (SC-9166, 1:1,000; Santa Cruz Biotechnology), phospho-GSK3β (SC-11757, 1:1,000; Santa Cruz Biotechnology), HES1 (SC-13844, 1:500; Santa Cruz Biotechnology), actin (SC-1616, 1:1,000; Santa Cruz Biotechnology), and α-tubulin (SC-32293, 1:1,000; Santa Cruz Biotechnology) at 4°C overnight. The membranes were then washed three times at 10-min intervals with Tris-buffered saline and Tween 20 (TBS-T; 1,000:1) buffer and incubated with secondary antibodies, including anti-mouse (SC-2005), -goat (SC-2020), or -rabbit (SC-2004) immunoglobulins (Igs) tagged with horseradish peroxidase (HRP) at room temperature for 1 h. Next, after washing with TBS-T buffer for 30 min, the immunoreactive proteins were visualized using an enhanced chemiluminescence (ECL) detection kit (Amersham Bioscience, Piscataway, NJ, USA), as previously described.[@bib90]^,^[@bib93], [@bib94], [@bib95]

Cell Proliferation and Viability Assays {#sec4.8}
---------------------------------------

For cell proliferation analysis, control (scramble-transduced), GPR50-knockdown, or GPR50-overexpressing cells (2 × 10^4^ cells/well) were seeded onto 12-well plates. Cells were counted, starting from 24 h up until day 5 using a trypan blue kit. For cell viability assays, cells were seeded onto 96-well plates, and at the indicated time points, EZ-cytox WST-1 reagent (DoGen, Seoul, Republic of Korea) was added at a ratio of 1:10 and incubated at 37°C in a humidified atmosphere of 5% CO~2~ for ∼4 h. Afterward, the relative absorbance was measured at 450 nm using a fluorescence microplate reader, as previously described.[@bib90]^,^[@bib93], [@bib94], [@bib95]

Wound Healing/Cell Migration Assay {#sec4.9}
----------------------------------

For the wound-healing assay, ∼90% confluent cells in 60 mm culture dishes were treated with mitomycin C (MMC; 10 μg/mL) for 3 h, after which, the cells were scratched with a 200-μL pipette tip. The indicated wound areas in the dishes were marked, and photos were taken every 12 h. The pictures were analyzed in ImageJ, and the wound closure percentage (%) was determined, as previously described.[@bib90]

Sphere Formation Assay {#sec4.10}
----------------------

The indicated cells (1 × 10^5^ cells) were seeded onto noncoated Petri dishes with sphere-forming medium containing serum-free DMEM/F12 media with B27 supplement, 20 ng/mL EGF (Sigma-Aldrich), 10 μg/mL insulin (Sigma-Aldrich), and 1% bovine serum albumin (Sigma-Aldrich). After 6 days, colonies were gently collected into conical tubes (SPL Lifesciences, Pocheon, South Korea) and stained with crystal violet (Sigma-Aldrich). Finally, the colonies were disassociated using 0.25% trypsin-EDTA (1×; Gibco, Thermo Fisher Scientific, Waltham, MA, USA), after which, the disassociated cells were counted and presented as the percent (%) of sphere-forming cells, as previously described.[@bib90]^,^[@bib94]

Drug-Resistance Assay {#sec4.11}
---------------------

For drug-resistance analysis, 1 × 10^5^ cells were seeded onto 12-well dishes and incubated overnight at 5% CO~2~ and 37°C. The cells were then treated with 0.5 μM doxorubicin and incubated for another 48 h at 5% CO~2~ and 37°C. After 48 h of incubation, the cells were counted and presented as the percent (%) of surviving cells, as previously described.[@bib90]

Luciferase Reporter Assay {#sec4.12}
-------------------------

For the luciferase assay, the indicated cells (1 × 10^5^ cells/well) were seeded onto 12-well plates and transiently transfected with 1 μg of either *HES1* or *HES5* luciferase plasmid using HyliMax transfection reagent (1:3 ratio; Dojindo).[@bib96] The cells were harvested after 48 h post-transfection, and luciferase activity was measured using a luminometer (Veritas microplate luminometer; Turnor Biosystems, Sunnyvale, CA, USA). Luciferase activity was normalized to β-galactosidase expression levels.

ADAM17 Activity Assay {#sec4.13}
---------------------

ADAM17 activity assay was performed using an ADAM17 Activity Assay Kit (CSB-E09315h; Cusabio Technology, Houston, TX, USA), according to the manufacturer's instructions.[@bib97] Briefly, 1 × 10^7^ cells were harvested in 1 mL of ice-cold PBS (pH 7.2--7.4) with protease inhibitor and stored at −20°C overnight. After two freeze-thaw cycles, the cell lysates were centrifuged for 5 min at 5,000 × *g* at 2°C--8°C, and then the supernatant was collected and stored at −20°C until future use, after measurement of the protein concentrations in the supernatant. Approximately 15 mg of protein was mixed with substrate for 15--30 min, and the optical density (OD) of each well was determined within 5 min using a microplate reader (x-Mark spectrophotometer; Bio-Rad Laboratories).

CoIP Assay {#sec4.14}
----------

To analyze protein interactions, a coIP assay was performed with the indicated samples. Briefly, 400 μg of cell lysate was pretreated with 30 μL Protein A/G Agarose beads (Santa Cruz Biotechnology) to remove nonspecific IgG. The supernatant was then collected in new tubes and incubated overnight with 3--4 μg primary antibodies (anti-GPR50 or anti-ADAM17) and rabbit IgG on an agitator at 4°C. Subsequently, Protein A/G Agarose was added, and the mixture was incubated for an additional 3 h and spun down at 4,000 × *g* for 1 min. The pellets were then washed thrice with ice-cold cell lysis buffer, after which, the immunoprecipitated proteins were analyzed by western blotting, as described above.

Statistical Analysis {#sec4.15}
--------------------

All experiments were performed three times, and the data are presented as the mean ± standard deviation (SD). For statistical analysis, an unpaired t test was performed between two groups (control versus treated), and p values \<0.05 were considered statistically significant.

Data Availability {#sec4.16}
-----------------

All data referenced in the manuscript can be downloaded from websites indicated in the Materials and Methods section.
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